Literature DB >> 7690439

Interleukin-12 enhances interleukin-3 dependent multilineage hematopoietic colony formation stimulated by interleukin-11 or steel factor.

R E Ploemacher1, P L van Soest, A Boudewijn, S Neben.   

Abstract

Interleukin 12 (IL-12: natural killer cell stimulatory factor, NKSF; cytotoxic lymphocyte maturation factor, CLMF) was studied for its effect on colony formation and lineage expression of low-density bone marrow cells from 5-fluorouracil-treated mice, and of sorted stem cells using a semi-solid culture assay in the absence or presence of IL-3, IL-11, Steel factor (SF) and erythropoietin. IL-12 did not support colony formation as a single factor, nor in the presence of IL-11 or SF. In IL-3-containing cultures, IL-12 slightly enhanced neutrophilic and monocyte differentiation. Both SF and IL-11 synergized with IL-3 to increase the percentage of multilineage colonies and the number of colonies containing erythrocytes, megakaryocytes, neutrophils, eosinophils, monocytes/macrophages, and blast cells, but not mast cells. In the presence of IL-3 + IL-11, IL-12 greatly enhanced neutrophil, megakaryocyte, erythrocyte, and mast cell development. In IL-3 + SF-containing cultures, IL-12 further increased colony numbers and a higher percentage of colonies expressed neutrophilic, megakaryocytic, erythroid, monocytic, blast cell, and/or mast cell lineages. Colony size and the presence of eosinophils in colonies were unaffected by IL-12 addition. These effects of IL-12 could not be reversed by antibodies against interferon-gamma. Our data show that IL-12 may act as a synergistic factor, stimulating multilineage expression of hemopoietic stem cells, probably via a direct action. The observed activity of IL-12, however, required the presence of a least two factors, i.e. either IL-3 + IL-11, or IL-3 + SF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690439

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

Review 1.  Immunobiology of interleukin-12.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

2.  Interleukin-12 and interferon-gamma. Do they always go together?

Authors:  G Trinchieri
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 3.  Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency.

Authors:  J Chehimi; G Trinchieri
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

4.  Endogenous interleukin-12 is involved in resistance to Brucella abortus infection.

Authors:  Y Zhan; C Cheers
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

5.  Role of interferon-gamma in interleukin 12-induced pathology in mice.

Authors:  B D Car; V M Eng; B Schnyder; M LeHir; A N Shakhov; G Woerly; S Huang; M Aguet; T D Anderson; B Ryffel
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

6.  HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates.

Authors:  Lena A Basile; Dolph Ellefson; Zoya Gluzman-Poltorak; Katiana Junes-Gill; Vernon Mar; Sarita Mendonca; Joseph D Miller; Jamie Tom; Alice Trinh; Timothy K Gallaher
Journal:  PLoS One       Date:  2012-02-24       Impact factor: 3.240

Review 7.  Interleukin 12: a new clinical player in cytokine therapy.

Authors:  R E Banks; P M Patel; P J Selby
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

8.  The stimulatory effects of interleukin (IL)-12 on hematopoiesis are antagonized by IL-12-induced interferon gamma in vivo.

Authors:  V M Eng; B D Car; B Schnyder; M Lorenz; S Lugli; M Aguet; T D Anderson; B Ryffel; V F Quesniaux
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

9.  Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice.

Authors:  Lena A Basile; Timothy K Gallaher; Darryl Shibata; Joseph D Miller; Dan Douer
Journal:  J Transl Med       Date:  2008-05-19       Impact factor: 5.531

10.  Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects.

Authors:  Mamata S Gokhale; Vladimir Vainstein; Jamie Tom; Simmy Thomas; Chris E Lawrence; Zoya Gluzman-Poltorak; Nicholas Siebers; Lena A Basile
Journal:  Exp Hematol Oncol       Date:  2014-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.